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Abstract
A novel chemocentric approach to identifying cancer-relevant targets is introduced. Starting with a large chemical
collection, the strategy uses the list of small molecule hits arising from a differential cytotoxicity screening on tumor HCT116
and normal MRC-5 cell lines to identify proteins associated with cancer emerging from a differential virtual target profiling
of the most selective compounds detected in both cell lines. It is shown that this smart combination of differential in vitro
and in silico screenings (DIVISS) is capable of detecting a list of proteins that are already well accepted cancer drug targets,
while complementing it with additional proteins that, targeted selectively or in combination with others, could lead to
synergistic benefits for cancer therapeutics. The complete list of 115 proteins identified as being hit uniquely by compounds
showing selective antiproliferative effects for tumor cell lines is provided.
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Introduction
Cancer is a disease of the cell [1]. This rather simple statement
implies an enormous complexity when attempting to identify
efficacious anticancer agents. One of the major issues associated
with anticancer research is that traditional target-directed
strategies are confronted with the essentiality of the function of
the target in healthy cells. Inevitably, targeting proteins that have
essential functions are likely to lead to chemical entities with
narrow therapeutic windows and significant toxic effects [2]. An
additional challenge is the unstable epigenetic and genetic status of
cancer cells, undergoing multiple mutations, gene copy alterations,
and chromosomal abnormalities that have a direct impact on the
efficacy of anticancer agents at different stages of the disease [3].
All these aspects make cancer drug discovery extremely difficult
and have led to poor clinical approval success rates compared to
other therapeutic areas [2].
The advent of high-throughput cell-based cytotoxicity assays
opened new perspectives for anticancer discovery [4]. The
implementation of differential cytotoxicity screens marked the
departure from small molecule screens on preconceived individual
protein targets and allowed the identification of small molecules
potentially acting through a richness of mechanisms of action [5],
while showing at the same time selective antiproliferative effects in
cancer cells compared to healthy cells [6]. However, as recently
pointed out [1], for those cell-based strategies to have a true
impact in cancer drug discovery, means to uncover the target
profile of bioactive small molecules in antiproliferative or toxicity
assays are absolutely necessary. In this respect, extensive
proteomic profiling is often applied subsequently to identify
differentially expressed proteins in cancer cell lines that may
explain the biological effect of small molecule hits [7,8]. However,
profiling the cellular activities of molecular libraries is both
technically and logistically a laborious task [9] and thus,
alternative approaches for fast and efficient profiling of hundreds
of compounds on thousands of proteins are required.
In recent years, the availability of an increasing amount of
protein-ligand interaction data in the public domain has promoted
the development of ligand-based computational methods aiming
at predicting the affinity profile of small molecules across multiple
targets [10]. An early application of these initiatives was the
prediction of the biological activity spectrum of all small molecules
contained in the National Cancer Institute database [11]. Lately,
virtual target profiling was successfully used to identify new targets
for known drugs [12], to predict the mechanism of action of
antimalarials discovered in a high-throughput cell-based screen
[13], and to suggest the targets against which selected compounds
from a chemical library should be tested, leading to the
identification of novel antagonists for all four members of the
adenosine receptor family [14]. Given the current levels of
performance achieved, in terms of sensitivity and specificity,
against experimentally-determined complete ligand-protein inter-
action matrices [15], these methods are emerging as a true fast and
efficient alternative to the more laborious proteomic profiling.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35582The integration of differential cytotoxicity screening and virtual
target profiling for the identification of cancer-relevant targets was
put into practice within the context of CancerGrid, a European
Commission project under Framework Programme 6 [16]. Details
on the approach followed and the results achieved are discussed in
the following sections.
Results
For the sake of clarity, a summary scheme of the overall
differential in vitro and in silico screening (DIVISS) process followed
in this work is depicted in Figure 1. Starting with a chemical
collection of 30,000 compounds, differential cytotoxicity screening
resulted in the identification of two sets of small molecule hits
showing selective antiproliferative effects for tumor and healthy
cells, respectively, which by virtual target profiling led ultimately to
the identification of a list of 115 proteins of potential relevance to
cancer. Details of the results obtained at each stage of this novel
chemocentric approach to cancer target identification are
provided next.
High-throughput cytotoxicity screening
A cell-based cytotoxicity screening campaign was performed on
a chemical collection composed of 30,000 diverse molecules
selected mainly from the entire AMRI catalogue [17]. Single point
screening of these compounds at 50 mM concentration was
completed in duplicate on a colon cancer HCT116 cell line.
The correlation of the two independent viability values determined
for each compound is depicted in Figure 2a. An average Z9 factor
of 0.58 was derived from analysis of these duplicate data, which is
indicative of the quality of the assay and the data obtained. The
distribution of the number of compounds resulting in different
average percentages of cell viability is provided in Figure 2b. As
can be observed, almost 50% of the compounds had basically no
effect on the viability of the HCT116 cells. But most interestingly,
over 13% of the compounds showed remarkable toxic effects on
HCT116 cells, with viability values of 20% or lower. This
cytotoxic set of 4,158 compounds was selected for a follow-up
dose-response screening.
Differential cytotoxicity dose-response screening
To optimise our capacity of dose-response screening, a diverse
set of 2,000 molecules was first selected from the 4,158 cytotoxic
compounds identified in the previous high-throughput screening
campaign [18]. Dose-response curves on both tumor HCT116
and normal MRC-5 cells were determined in duplicate for these
2,000 compounds. To identify those small molecules that have
levels of toxicity on tumor cells significantly higher than those
observed on healthy cells, the ratio between the IC50 values
obtained in MRC-5 cells, IC50 (MRC-5), and those obtained in
HCT116 cells, IC50 (HCT116), was derived for each compound.
A total of 230 compounds were identified to be 5 times or more
cytotoxic in tumor cells than in healthy cells (IC50 MRC-5/IC50
HCT116$5). A chemotype clustering analysis [19] was then
performed on this first set of 2,000 compounds for which dose-
response data was produced. A cytotoxicity enrichment score was
then assigned to each chemotype cluster based on its relative
presence in the set of 230 compounds showing most selective
antiproliferative effects on tumor cells. Those chemotypes having
higher than 20% hit rate were selected and used to recover
compounds from the remaining 2,158 for which only single-point
measurements were available. This bias towards selective tumor
cytotoxic chemotypes led to the identification of 150 compounds
that were complemented with an additional set of 330 compounds
added on the basis of diversity criteria [18]. Dose-response curves
on both cell lines were obtained in duplicate for these 480
compounds, from which an additional set of 35 compounds was
identified as having cytotoxic selectivity for tumor cells relative to
Figure 1. Schematic flowchart of the DIVISS approach applied in this work leading to the identification of 115 proteins of potential
relevance to cancer.
doi:10.1371/journal.pone.0035582.g001
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differential cytotoxicity dose-response in vitro screening, leading
to the identification of 265 compounds with selective cytotoxicity
for tumor cells (Figure 1). Overall, 119,520 cytotoxicity data points
were generated, 60,000 from the primary cytotoxicity screenings
on HCT116 cells (30,000 compounds in duplicate) and 59,520
from the dose-response screenings (2,480 compounds at 6
concentrations in duplicate on two cell lines), which represents a
significant screening effort.
The distributions of the resulting average IC50 values for all
2,480 compounds on tumor HCT116 and normal MRC-5 cells
are illustrated in Figure 3a. The fact that most screened
compounds have determined IC50 values below 25 mM is a good
indication of the validity of the first screening. In this respect, just
over 12% of the compounds for tumor cells, compared to the
almost 26% for normal cells, gave an IC50 value above 25 mM,
whereas 25% and 22% of the compounds screened on tumor and
normal cells, respectively, returned an IC50 value below 5 mM.
The final distribution of the cytotoxicity ratios per compound is
provided in Figure 3b, where large values are associated to
promising compounds having some degree of selective cytotoxicity
for tumor cells relative to healthy cells. As can be observed, the
vast majority of compounds (over 60%) returned cytotoxicity ratios
between 0.5 and 2 meaning that they were basically unselective
between tumor and healthy cells. But most interestingly, 711
compounds (29%) were found to be 2 times or more cytotoxic in
tumor cells than in healthy cells, with 265 of them showing
cytotoxicity ratios above 5. In contrast, 277 compounds (11%)
were found to be 2 times or more cytotoxic in healthy cells than in
tumor cells, with 251 of them having cytotoxicity ratios below 0.2.
These two sets of 265 and 251 compounds (Figures S1 and S2)
showing selective antiproliferative effects for tumor and normal
cells, respectively, will be carried over to the next phase of virtual
target profiling (Figure 1). A similarity analysis (Figure S3)
highlighted the diversity of chemical structures within each set
but also between the two sets, a point worth stressing in support of
phenotypic screening approaches over target-directed strategies
for complex diseases.
Virtual target profiling
Each one of the two cell-line selective compound sets was
processed in silico against the 4,643 ligand-based protein models
derived from publicly available resources [20–28] using a validated
similarity-based approach described earlier [14,15]. With regards
to the 265 selective tumor cytotoxic compounds, at least one target
interaction was predicted for 173 of them (65%), reflecting that the
chemical space defined by the set of tumor selective compounds
was decently covered by small molecules present in public
chemogenomic databases. For these compounds, a total of 2,356
molecule-protein interactions were predicted. Of those, 818
interactions between 139 molecules and 229 proteins were
predicted to have activities of 1 mM or better (pAct$6), meaning
that on average each tumor selective compound was expected to
potentially interact with 6 targets. In comparison, at least one
target interaction was predicted for 117 of the 251 selective
cytotoxic compounds on normal cells (47%), meaning that 53% of
those compounds was found to be outside the applicability domain
defined by small molecules in public chemogenomic databases
[15]. For these compounds, a total of 1,023 molecule-protein
interactions were predicted. Of those, 463 interactions between 84
molecules and 160 proteins were predicted to have activities of
1 mM or better (pAct$6), resulting in an average number of 5
interacting proteins per compound.
A comparative analysis of the predicted interactions from the
two cell-line selective compound sets allows gaining a better insight
on the proteins likely to be differentially relevant for tumor cell
lines. The results are illustrated in the Venn diagram depicted in
Figure 4a, which schematically shows the degree of overlap and
Figure 2. a) Correlation of two independent viability values determined for the same compound and b) distribution of viability
values for the chemical library of 30,000 compounds.
doi:10.1371/journal.pone.0035582.g002
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found that up to 114 proteins were predicted to be hit at least once
by some compound in either set, with the list of proteins being
mainly composed by G protein-coupled receptors (45%) and
enzymes (37%). In contrast, only 46 proteins were found to be
solely hit by compounds with selective cytotoxicity for healthy
cells, with a distribution among protein families very similar to the
one obtained previously for the list of shared proteins (41% of G
protein-coupled receptors and 37% of enzymes). But most
interestingly, a list of 115 proteins hit uniquely by compounds
with selective cytotoxicity for tumor cells was identified (Table S1).
Analysis of its composition among the main protein families of
therapeutic relevance reveals a clearly differentiated signature
from the other two lists of proteins. As shown in Figure 4b, the list
is mainly composed of enzymes (58%) and the presence of G
protein-coupled receptors has been reduced significantly (16%).
To complement this picture, Figure 4c provides the class
distribution of the 67 enzymes found in this list. A clear bias
towards transferases (43%) is observed, very much in agreement
with the importance conferred to kinases as therapeutic targets for
cancer [29,30].
Proof of concept
It may not escape the scrutinous eye of the cancer researcher
that within the list of 115 potential tumor selective proteins (Table
S1) there are two widely recognized anticancer targets, namely,
histone deacetylases (HDACs) and heat shock protein 90-alpha
(HSP90), both of which known to be expressed in colon cancer
HCT116 cell lines [7,8] and to confer tumor selectivity upon small
molecule inhibition [31,32]. Accordingly, in an attempt to close
the cycle of the DIVISS approach presented above, inhibitors of
these two targets were used to exemplify at this stage that indeed
selective antiproliferative effects can be achieved on the tumor
HCT116 and normal MRC-5 cell lines used in this work.
To this end, suberoylanilide hydroxamic acid (SAHA) and 17-
(allylamino)-17-demethoxygeldanamycin (17AAG) were selected
as representative pan-HDAC and HSP90 inhibitors, respectively.
Dose-response curves on both HCT116 and MRC-5 cell lines
were determined for the two inhibitors (Figure S4). The results
confirmed that both compounds inhibited the proliferation of
HCT116 cells in a dose dependent manner, while having little or
no effect on MRC-5 cells. In particular, the IC50 values of SAHA
and 17AAG on HCT116 cells were 0.64 mM and 0.2 mM,
respectively, which resulted in 781 and 93 fold selectivity,
respectively, relative to the antiproliferative effect on MRC-5
cells. These observations provide confirmation of the ability of the
DIVISS approach for identifying cancer-relevant targets.
We checked also whether within the set of 265 compounds
showing selective antiproliferative effects for tumor cell lines there
was any compound that could have been tested on a range of
colon cancer cell lines and for which screening data was also
available in the public domain. Much to our surprise, we found
experimental data in PubChem [23] for eight compounds that
were also present in our tumor selective set (Table S2). Among
them, five compounds are reported to have affinity for the amine
oxidase flavin-containing B enzyme (MAO-B), a target present in
our list of 115 putative cancer-relavant proteins (Table S1). But,
most interestingly, one of them, NSC680350 (CID 387030), was
reported to have an IC50 of 80 nM for MAO-B, in good
agreement with our predictions. In addition, it was also tested at
multiple human tumor cell lines, including six colon cancer cell
lines. Among them, the pGI50 value reported in PubChem for
colon HCT116 cell lines (4.64) is, within the variability limits of
this type of experiments, in good agreement with the pGI50 value
obtained in this work for the same type of cell lines (5.19). The
dose-response curve of the cytotoxicity of NSC680350 on
HCT116 cell lines in this work and a summary of all colon
cancer data found in PubChem for this compound is provided in
Figure S5.
Discussion
Substantiation of the potential relevance to cancer of the list of
115 proteins identified as being targeted solely by tumor selective
compounds was performed by two independent perspectives. On
the one hand, all 115 proteins were scored on the basis of recently
derived oncogene probabilities (OncoScores) and checked for
currently available experimental data on the up- and down-
regulation in colon cancer samples [33,34]. On the other hand, we
used all drug-target interaction data available from public
resources [20–28] to rank order all drugs based on the number
of known targets within the list of 115 proteins and check for
whether cancer was the primary indication among the top ranked.
The results provide ample support for the use of the DIVISS
approach to identifying cancer-relevant targets.
The OncoScores for all 115 proteins targeted by tumor selective
compounds were obtained from the CGPrio website [34]. To
assess whether this list of proteins is enriched with probable
Figure 3. a) Distribution of the cytotoxicity (IC50 values) of the selected compounds on HCT116 and MRC5 cells and b) distribution
of the selective cytotoxicity against HCT116. NT means ‘‘non toxic’’.
doi:10.1371/journal.pone.0035582.g003
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also calculated for all the 46 proteins targeted by normal selective
compounds and the 114 proteins shared by the two sets of cell-line
selective compounds. The trends of the cumulative percentage of
proteins with OncoScores above a certain probability value found
within each list are displayed in Figure 5. As can be observed, it is
found that 36.5% of the 115 proteins targeted by tumor selective
compounds have an oncogene probability above 0.7 and that,
under the same OncoScore cutoff, this percentage is significantly
higher than the 8.7% and 19.3% of the 46 proteins targeted by
normal selective compounds and the 114 proteins shared by the
two sets of compounds, respectively. Having provided evidence
that this selection of 115 tumor selective proteins is enriched with
putative oncogenes, the IntOGen platform [33] was then used to
inspect whether any protein from the list was in addition known to
be significantly altered (corrected p-value ,0.05) in terms of up- or
down-regulation in colon cancer. A total of 29 of those proteins
(25%) could indeed be confirmed to be significantly altered in
colon cancer, 10 of which having an OncoScore above 0.7. The
OncoScores and regulation marks for the whole list of 115 tumor
selective proteins are provided Table S1.
The subset of 42 tumor selective proteins with OncoScore
higher than 0.7 is provided in Table 1. Not surprisingly, its
composition is highly biased by protein kinases (52%), although
there is also an important representation (21%) of transcription
factors. Of mention is however the fact that a couple of G protein-
coupled receptors (GPCRs) are found in this highly probable
oncogene subset, namely, the D(1A) dopamine receptor (DRD1)
and the sphingosine 1-phosphate receptor 1 (S1PR1). GPCRs
have traditionally been regarded as the main targets for diseases of
the central nervous system. But most interestingly, the relevance of
GPCRs in cancer drug discovery was revisited recently and the
potential role of S1PR1 in particular highlighted [35].
A close look at the top-20 ranked proteins present in Table 1
reveals that the list contains proteins that may be somewhat
unexpected from the viewpoint of its relationship to colorectal
cancer. For example, the androgen (AR) and estrogen (both ESR1
and ESR2) nuclear hormone receptors are known to be relevant in
prostate and breast cancers, and the alpha-type platelet-derived
(PDGFRA) and epidermal (EGFR) growth factor receptors are
recognised angiogenesis factors. However, recent studies suggest a
role in intestinal carcinogenesis for nuclear receptors in general
[36] and growth factor receptors [37], including precisely AR [38],
ESR1 [39], ESR2 [40], PDGFRA [41] and EGFR [42].
PDGFRA in particular is also known to be significantly down-
regulated in colon cancer [33]. In addition, further evidences exist
in the literature of drugs targeting primarily some of those targets
and having an effect on the proliferation of human colorectal
tumour cell lines, including HCT116 [40,43]. Among them,
raloxifene is a high affinity binder of both ESR1 and ESR2 and
has been reported to inhibit HCT116 cell growth in a dose-
dependent manner [40] and afatinib is a potent EGFR inhibitor
that was recently shown to inhibit the growth of HCT116 cell lines
with an IC50 value of 1.62 mM [43]. These examples provide
ample bibliographical support to the relevance in colon cancer for
some of those proteins that would have been otherwise completely
overlooked.
It may also surprise that currently recognised cancer targets,
such as HSP90, are not present in Table 1. In this particular case,
the target is indeed contained in the full list of 115 proteins
provided in Table S1 but with a low OncoScore=0.023. It is thus
worth stressing here that CGPrio [34] is a machine learning
method based on the differential properties of known cancer genes
and on the assumption that genes with similar properties
(including sequence conservation, protein domains and interac-
tions, and regulatory data) to known cancer genes are more likely
to be involved in cancer. It is used here as a prioritization method,
as it has been shown that a large percentage of new cancer genes
have high CGPrio probabilities [33,34], but it doesn’t mean that
absolutely all cancer genes share these properties, and thus there
Figure 4. a) Venn diagram of the protein targets predicted for the selective cytotoxic compounds to HCT116 and MRC-5 cell lines;
b) distribution across protein families of the 115 targets predicted to interact uniquely with selective cytotoxic compounds to
tumor cells; and c) distribution across enzyme classes of the 67 enzymes present in the list of 115 putative cancer targets.
doi:10.1371/journal.pone.0035582.g004
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low CGPrio probability. In this respect, the low OncoScore
obtained for HSP90 means only that, on the basis of current
knowledge on cancer genes, HSP90 does not share properties with
the rest of cancer genes for which information is available. Taken
together, these results emphasize the potential applicability of the
DIVISS approach as a complementary strategy to the identifica-
tion of cancer-relevant targets.
The BioCarta resource [44] was then used to perform an analysis
of the main pathways in which these 42 highly probable oncogenes
are involved. A total of 131 pathways were retrieved, with 68 of
them (52%)having twoormore proteins and only 9 (7%) containing
five or more proteins. The latter group is composed mainly of
signaling pathways. Among them, the MAPKinase signaling
pathway contains seven of those probable oncogenes, namely,
BRAF, MAP2K1, MAP3K8, MAPK10, RAF1, STAT1, and
TGFBR1, and the Erk1/Erk2 MAPK signaling pathway involves
six of them, namely, EGFR, MAP2K1, PDGFRA, RAF1, SRC,
and STAT3 (see Table 1). The remaining 7 pathways are the
Bioactivepeptideinduced,EGF,andPDGF signaling pathways,the
signaling of hepatocyte growth factor receptor, and the ones
defining the role of ERBB2 in signal transduction and oncology, the
CARM1 and regulation of the estrogen receptor, and the
sumoylation by RANBP2 regulates transcriptional repression, all
involving5 ofthoseprobable oncogenes(Table 1).The link between
some of these pathways and cancer has been already recognised in
previous studies [45,46].
In recent years, the amount of publicly available in vitro data on
the interaction of drugs with multiple proteins has increased
dramatically [20–28]. Analysis of these data has revealed that most
cancer drugs are multitarget agents rather than selective molecules
[47]. Accordingly, we took the list of 115 targets hit by selective
compounds on HCT116 and performed a search for those drugs
that, based on currently available affinity data determined
experimentally [20–28], would show at least micromolar affinity
on the largest number of those targets. Figure 6 collects the results
obtained for the 20 drugs having at least micromolar affinity for
more than 5 tumor selective proteins. Remarkably, 18 of those
drugs have cancer as their primary indication, 4 of which target
mainly HDACs, whereas the other 14 have different affinity
profiles on a wide range of kinases. The presence of chlorprom-
azine and amitriptyline in this list, indicated for psychosis and
depression, respectively, and targeting mainly GPCRs instead of
HDACs or kinases, may come as a surprise at this stage. However,
in the line of what was previously mentioned about the new
perception of GPCRs in cancer [35], recent reports indicate that
chlorpromazine, potentially through its action on multiple tumor
selective GPCRs, can change influx properties of membranes and
that this property makes it a promising chemosensitizing
compound for enhancing the cytotoxic effect of tamoxifen, an
antagonist of the estrogen receptor, present also in the list of 115
tumor selective proteins [48]. From a drug perspective, these
results provide further support to the relevance for cancer of the
115 proteins identified.
There are two recognisable extensions to the version of the
DIVISS approach presented here. The first obvious extension is in
the use of other cell lines. In this particular study, HCT116 and
MRC-5 cell lines have been taken as models of tumor and healthy
cell lines, respectively. However, there are numerous alternative
human tumor cell lines that can be used instead and those can in
turn be differentially compared to several healthy cell lines as well
[49]. Accordingly, differential anticancer screens on each
particular combination of tumor and healthy cell lines will in
principle lead to different, yet complementary, lists of cancer-
relevant targets. The second potential extension is in the coverage
of larger chemical spaces, an aspect that is inherent to any
screening campaign. The present study focussed on a diverse
selection of 30,000 molecules from the AMRI catalogue, currently
containing over 240,000 compounds. The size and nature of the
chemical library used in the differential cytotoxicity screens
essentially determines the number and diversity of small molecule
hits identified and they ultimately define the type of targets that, by
means of in silico target profiling, will be selectively associated to
each cell line.
Figure 5. Distribution of oncogene probabilities for the proteins predicted uniquely for compounds selective to HCT116 (black)
and MRC-5 (light grey) and the proteins found in both selective sets (dark grey). NA collects all proteins for which oncogene probabilities
were not available from CGPrio [34].
doi:10.1371/journal.pone.0035582.g005
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Cell systems are implicitly robust and selectively acting on one
particular target may not be the most efficacious way of
modulating or interfering with them as the system may always
find ways to compensate for the selective perturbation incorpo-
rated. Instead, targeting multiple essential targets in tumor cells
may be a more efficient strategy to make more difficult for the cell
system to compensate for all perturbations introduced. Indeed,
recent evidences indicate that most cancer drugs attain their in vivo
efficacy through modulation of multiple targets rather than
Table 1. List of 42 proteins with OncoScore .0.7 among the 115 proteins identified by the DIVISS approach.
No. Protein Name Gene Name OncoScore
1 Alpha-type platelet-derived growth factor receptor PDGFRA Q 1.000
2 Androgen receptor AR 1.000
3 Angiopoietin-1 receptor TEK 1.000
4 B-Raf proto-oncogene serine/threonine-protein kinase BRAF 1.000
5 Epidermal growth factor receptor EGFR 1.000
6 Estrogen receptor ESR1 1.000
7 FL cytokine receptor FLT3 1.000
8 Hepatocyte growth factor receptor MET q 1.000
9 Mast/stem cell growth factor receptor KIT Q 1.000
10 Proto-oncogene tyrosine-protein kinase ABL1 ABL1 1.000
11 Proto-oncogene tyrosine-protein kinase Src SRC 1.000
12 RAF proto-oncogene serine/threonine-protein kinase RAF1 1.000
13 Vascular endothelial growth factor receptor 1 FLT1 1.000
14 Vascular endothelial growth factor receptor 3 FLT4 1.000
15 Cell division protein kinase 2 CDK2 0.999
16 Nuclear factor of activated T-cells, cytoplasmic 1 NFATC1 0.999
17 Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP1A Q 0.999
18 Signal transducer and activator of transcription 3 STAT3 0.999
19 Cell division protein kinase 5 CDK5 0.998
20 Estrogen receptor beta ESR2 0.998
21 Glycogen synthase kinase-3 alpha GSK3A 0.996
22 Proto-oncogene tyrosine-protein kinase FGR FGR 0.992
23 Mitogen-activated protein kinase kinase kinase 8 MAP3K8 q 0.984
24 Short transient receptor potential channel 4 TRPC4 0.981
25 Histone deacetylase 4 HDAC4 0.975
26 Mitogen-activated protein kinase 10 MAPK10 0.974
27 TGF-beta receptor type-1 TGFBR1 0.970
28 E3 ubiquitin-protein ligase Mdm2 MDM2 q 0.966
29 Histone deacetylase 7 HDAC7 0.959
30 Peroxisome proliferator-activated receptor gamma PPARG 0.959
31 Histone deacetylase 9 HDAC9 Q 0.953
32 Acyl-CoA desaturase SCD q 0.940
33 Dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 0.895
34 Histone deacetylase 1 HDAC1 0.895
35 Histone deacetylase 6 HDAC6 0.895
36 D(1A) dopamine receptor DRD1 0.866
37 Sphingosine 1-phosphate receptor 1 S1PR1 0.863
38 Signal transducer and activator of transcription 1-alpha/beta STAT1 q 0.824
39 Krueppel-like factor 5 KLF5 Q 0.745
40 Poly [ADP-ribose] polymerase 1 PARP1 0.711
41 Phosphatidylinositol-4,5-bisphosphate 3-kinase PIK3CD 0.708
42 Cyclin-dependent kinase 5 activator 1 CDK5R1 0.701
The OncoScore is the oncogene probability calculated from CGPrio [34].The arrows next to the gene name mark the set of 10 proteins from this list that are known to be
significantly altered (corrected p-value ,0.05) in terms of up- or down-regulation in colon cancer, as extracted from the IntOGen platform [33].
doi:10.1371/journal.pone.0035582.t001
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defining the essential protein signature of each cancer type, so it
can be thoroughly addressed by novel cancer therapeutic agents
[50]. The DIVISS strategy presented here represents a novel
chemocentric approach to the identification of cancer-relevant
drug targets that complements efficiently other established
bioinformatics and functional approaches [51,52] and thus may
contribute to increasing our confidence on potential drug targets
[53].
Materials and Methods
Screening Library
The CancerGrid consortium had privileged access to the entire
chemical catalogue at AMRI [17], currently containing 241,000
compounds and found particularly relevant for drug discovery
purposes in a comparative analysis of 23 supplier databases [54].
This relatively vast, diverse and unique chemical space was
complemented with a focused set of 1,500 compounds synthesized
Figure 6. Profiles of experimental affinity data of the 20 drugs, among 4,819, hitting more than 5 targets found solely in tumor
selective compounds. Only affinities above 1 mM are considered. Color coding reflects pAffinity ranges: white 6–7; light grey 7–8; dark grey 8–9;
black .9. Color codes for targets refer to HDACs (yellow), kinases (orange), and other (green).
doi:10.1371/journal.pone.0035582.g006
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our screening capacity, an optimal diversity selection was
performed [55]. The final screening collection was limited to a
diverse selection of 30,000 compounds, a number that was fitting
optimally our capacity for cytotoxicity screening.
Cell types and culture conditions
A colon adenocarcinoma (HCT116) and normal human lung
fibroblast (MRC-5) cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas, VA). HCT116 cells
were maintained in McCoy’s 5a Modified Medium supplemented
with 10% FBS, 100 units/ml penicillin, and 100 mg/ml strepto-
mycin at 37uC in a humidified 5% CO2 incubator. Subculturing
was done using 1:5 ratio twice a week. MRC-5 cells were
maintained in DMEM supplemented with 10% FBS, 100 units/ml
penicillin, and 100 mg/ml streptomycin at 37uC in a humidified
5% CO2 incubator. Subculturing was done using 1:3 ratio twice a
week. A cell bank was established for the cell lines used during the
differential toxicity screening campaign. In all experiments, the
doubling time between cancer and normal cells was approximately
24 hours.
Assay developments and validation
The high-throughput in vitro assay for measuring toxicity and
antiproliferative effects of small molecules was implemented as
described earlier [56]. Cell lines were grown in culture flasks to 90%
confluences, then harvested in counted cell density and seeded into
384-well microtiter plates. Test compounds were then added in
various concentrations (in 2% DMSO final concentration) and
incubated with the cells in CO2 incubators at 37uC for 48 h. This
incubation period has the advantage of allowing those compounds
that are not directly toxic but can block or slow down cell
proliferation to have enough time to show their effect. During this
period, FBS content of the medium was decreased to avoid the
masking effect of FBS on toxicity. Detection of viability is based on
the reduction of resazurin (Alamar blue) by living cells, resulting in
an increased fluorescent signal [57]. For the transformation of the
assay into a high-throughput format, a Beckman Biomek liquid
handling system and a Wallac Victor plate reader were used.
Protocols needed for handling the 384-well plates were established
for both single-concentration screening and dose-response curve
determination. A plate map was used for the validation of the assay
on 384-well plates, which is suitable for the determination of dose-
response curves for 16 compounds at the same time using 6
concentrations in triplicate. This experiment was run in parallel on
5 plates and repeated three times on different days. From the dose-
response curves, IC50 values were determined and analyzed. To test
the reproducibility and robustness of the assay for high-throughput
screening, Z9 factors (,0.72) and S/B ratios (,10) were determined
and the respective plate-to-plate and day-to-day coefficients of
variation found to be 5.0%, 2.7%, 1.7% and 5.6%. Based on the
established assay protocol, single-point screenings were done at
50 mM compound concentration in duplicate. Likewise, IC50 values
were obtained from the toxicity dose-response curves from six
compound concentrations in duplicate and calculated with Micro-
cal Origin 5.0. Compounds showing selective cytotoxicity for tumor
cells relative to healthy cells are identifiedby large valuesof the ratio
IC50(MRC-5)/IC50(HCT116), whereas the inverse of this ratio
serves to recognize compounds with selective cytotoxicity for
healthy cells relative to tumor cells.
Chemogenomic databases
There are currently several public sources that contain chemical
structures with information on the binding or functional activity to
protein targets. Those used in the present work include
ChEMBLdb [20], PDSP [21], IUPHARdb [22], PubChem [23],
DrugBank [24], BindingDB [25], BindingMOAD [26], AffinDB
[27], and NRacl [28]. Altogether contain a total of 329,303 unique
ligands with 1,505,348 interactions to 4,643 unique proteins.
Among them, there are 4,819 small-molecule drugs with 30,875
interactions to 4,120 unique protein targets.
Affinity predictions and validation
To be processed efficiently, molecular structure information
needs to be encoded using some sort of mathematical descriptors.
In this work, three types of two-dimensional descriptors were used,
namely, SHED, FPD, and PHRAG [58,59], each one of them
characterizing chemical structures with a different degree of
fuzziness and thus complementing each other in terms of structural
similarity and hopping abilities. For any biological target under
study, the ensemble of molecular descriptors capturing the
structural and pharmacophoric features of all molecules for which
affinity data is publicly available from chemogenomic databases
represents a mathematical description of this target from a
chemical perspective. On this basis, the affinity of a compound
for a given target can be estimated by inverse distance weighting
interpolation of the experimental affinities from all neighboring
molecules found within a pre-determined applicability domain
[15]. Based on the ligand-based target models defined from all the
pharmacological data available in chemogenomic databases, each
small molecule can be currently processed against 4,643 proteins.
The output returns a list of the targets for which affinity is
predicted for every query molecule. The method has been
successfully validated retrospectively, on its ability to predict the
entire experimental interaction matrix between 13 antipsychotic
drugs and 34 protein targets [15], but also prospectively, on its
capacity to identify the correct targets for all molecules contained
in a biologically-orphan chemical library [14] and to correctly
anticipate the affinity profile of the drug cyclobenzaprine on a
panel of 8 protein targets [60].
Oncogene expression and probabilities
Expression profiles for proteins in various types of cancer were
directly extracted from IntOGen [33]. IntOGen is a framework
that currently contains and integrates data from almost 800
independent experiments collecting transcriptomic alterations,
genomic gains and losses, and somatic mutation information in
different human cancer types. Oncogene probabilities (Onco-
Scores) were calculated with CGPrio [34] using the PC-GS-PD-
PI-RD dataset that integrates a set of heterogeneous data
accounting for protein conservation (PC), gene structure (GS),
protein domains (PD), protein-protein interactions (PI), and
regulatory data (RD).
Small molecule inhibitors
SAHA, a pan-HDAC inhibitor, was kindly provided by Ciro
Mercurio (DAC s.r.l., Milan, Italy) with 95% purity and 17AAG, a
HSP90 inhibitor, was obtained from Sigma (St Louis, MO) with
95% purity.
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